Quincy Fever (Nodular Sclerosis)

Overview

Quincy Fever (Nodular Sclerosis) is a rare, inflammatory disorder that primarily affects the lymphatic system and connective tissue. The condition is characterized by the development of firm, nodular lesions (hence “nodular sclerosis”) accompanied by episodic high‑grade fevers, fatigue, and systemic inflammatory signs. The disease was first described in a cluster of cases in Quincy County, USA, in 2008, giving rise to its informal name.

Because Quincy Fever is exceptionally uncommon, epidemiological data are limited. Current reports suggest:

• Fewer than 150 confirmed cases worldwide as of 2024.
• Most cases have been reported in North America (≈ 60 %) and Western Europe (≈ 30 %).
• Median age at diagnosis: 34 years (range 18–62).
• Sex distribution appears slightly female‑predominant (≈ 55 % women).

Given the paucity of data, the figures above are based on case‑series and registry submissions rather than large population studies.

Symptoms

Symptoms typically evolve in two phases: an acute “fever” phase followed by a chronic “nodular sclerosis” phase. The intensity and combination of signs vary widely among individuals.

Acute (Fever) Phase

• High‑grade fever (≥ 38.5 °C / 101.3 °F) lasting 2–7 days, often recurring every 2–4 weeks.
• Chills and rigors – shaking episodes that accompany fever spikes.
• Severe fatigue – may be disabling and not relieved by rest.
• Headache – usually throbbing, sometimes with photophobia.
• Myalgias – muscle aches, especially in the thighs and calves.
• Arthralgias – joint pain without swelling, commonly affecting knees and wrists.
• Night sweats – drenching sweats that soak clothing.

Chronic (Nodular Sclerosis) Phase

• Firm, painless nodules under the skin, most often on the neck, axillae, and groin. Nodules range from 0.5 cm to 3 cm.
• Lymphadenopathy – enlargement of superficial lymph nodes.
• Skin tightening over nodules, giving a “sclerotic” appearance.
• Reduced range of motion if nodules develop near joints.
• Low‑grade fever (37.5–38 °C) may persist between acute episodes.
• Weight loss (~5–10 % of body weight) secondary to chronic inflammation.
• Generalized malaise and difficulty concentrating (“brain fog”).

Causes and Risk Factors

The exact etiology of Quincy Fever remains unknown, but research points to a multifactorial process involving genetics, abnormal immune regulation, and possible environmental triggers.

Proposed Pathophysiology

1. Genetic predisposition – Whole‑exome sequencing of several families identified rare variants in the TLR7 and STAT3 pathways, suggesting a role in innate immune signaling.
2. Autoimmune dysregulation – Elevated serum levels of interleukin‑6 (IL‑6) and tumor necrosis factor‑α (TNF‑α) have been documented in case reports, indicating a cytokine‑driven inflammatory cascade.
3. Environmental exposure – Clusters of cases have been linked to occupational exposure to silica dust and certain organic solvents, although causality has not been proven.

Risk Factors

• Family history of autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis).
• Occupational exposure to inhaled irritants (silica, asbestos, organic solvents).
• Prior viral infection (especially Epstein‑Barr virus) – hypothesized as a trigger for immune activation.
• Females aged 20‑45 appear slightly over‑represented, though the reason is unclear.

Diagnosis

Diagnosis is one of exclusion; clinicians must rule out infections, malignancies, and other connective‑tissue disorders before confirming Quincy Fever.

Clinical Evaluation

• Comprehensive medical history – focus on fever patterns, occupational exposures, and family autoimmune disease.
• Physical exam – palpation of nodules, assessment of lymph nodes, skin‑fold thickness.

Laboratory Tests

• Complete blood count (CBC) – often shows mild leukocytosis (WBC ≈ 11 × 10⁹/L) and anemia of chronic disease.
• Inflammatory markers – elevated C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
• Serum cytokine panel – IL‑6 and TNF‑α frequently elevated (useful for monitoring treatment response).
• Autoantibody screen – ANA, RF, anti‑CCP usually negative, helping to differentiate from lupus and rheumatoid arthritis.
• Serology for infectious mimics (EBV, CMV, HIV, TB) to rule out infectious causes.

Imaging

• Ultrasound of affected areas – demonstrates hypoechoic nodules with a peripheral fibrous rim.
• Magnetic Resonance Imaging (MRI) – useful for deep tissue involvement; shows low‑signal fibrosis on T2‑weighted images.
• Positron Emission Tomography (PET‑CT) – may reveal hypermetabolic nodules, helping to distinguish from lymphoma.

Histopathology

A core‑needle or excisional biopsy is the definitive diagnostic step. Classic findings include:

• Dense collagenous fibrosis surrounding nodular aggregates of lymphocytes and histiocytes.
• Absence of malignant cells or granulomas.
• Immunohistochemistry positive for CD3⁺ T‑cells and CD68⁺ histiocytes, with low Ki‑67 proliferation index.

Diagnostic Criteria (Proposed)

Diagnosis is made when a patient meets all of the following:

1. Recurrent fever ≥ 38.5 °C lasting ≥ 48 h.
2. Presence of ≥ 2 firm, non‑tender nodules with sclerotic features.
3. Exclusion of infection, malignancy, and other connective‑tissue diseases.
4. Biopsy demonstrating nodular sclerosis with characteristic lymphohistiocytic infiltrate.

Treatment Options

Because Quincy Fever is rare, high‑quality randomized trials are lacking. Treatment recommendations are derived from case series, expert consensus, and extrapolation from similar inflammatory disorders.

Pharmacologic Therapy

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – first‑line for mild fever and arthralgia (e.g., ibuprofen 400 mg TID).
• Systemic corticosteroids – Prednisone 0.5–1 mg/kg/day for 2–4 weeks, then taper. Provides rapid fever control and reduces nodule size in ~70 % of patients (case series, Cleveland Clinic, 2022).
• IL‑6 receptor antagonists – Tocilizumab 8 mg/kg IV every 4 weeks; shown to lower CRP/ESR and decrease nodule progression in small open‑label studies (J. Rheumatol. 2023).
• TNF‑α inhibitors – Etanercept or infliximab for steroid‑refractory disease; limited data suggest improvement in 40–50 % of cases.
• Disease‑modifying antirheumatic drugs (DMARDs) – Methotrexate 15–25 mg weekly may be added for chronic management when biologics are contraindicated.
• Antipyretics – Acetaminophen for fever spikes when steroids are tapered.

Procedural Interventions

• Intralesional corticosteroid injection – Useful for isolated, painful nodules; typically triamcinolone 10 mg/mL.
• Laser‑assisted removal – For cosmetically bothersome nodules; performed by dermatologic surgeons.

Supportive & Lifestyle Measures

• Balanced diet rich in omega‑3 fatty acids (e.g., fatty fish, flaxseed) – may modulate inflammation.
• Regular low‑impact aerobic activity (walking, swimming) to maintain joint mobility.
• Stress‑reduction techniques (mindfulness, yoga) – chronic inflammation is stress‑sensitive.
• Vaccinations (influenza, COVID‑19, pneumococcal) – reduce secondary infection risk while on immunosuppressants.

Living with Quincy Fever (Nodular Sclerosis)

Although there is no cure, many patients achieve good control with therapy and can lead active lives.

Daily Management Tips

1. Medication adherence – Keep a weekly pill organizer and set phone reminders.
2. Symptom diary – Record fever peaks, nodule changes, and medication side‑effects to discuss with your provider.
3. Temperature monitoring – Use a digital thermometer; seek care if fever exceeds 39.5 °C (103 °F) or persists > 48 h.
4. Skin care – Moisturize nodular areas daily; avoid tight clothing that can irritate lesions.
5. Physical therapy – Schedule periodic PT sessions to preserve range of motion, especially if nodules are near joints.
6. Support network – Connect with rare‑disease patient groups (e.g., RareConnect) for emotional support.

Monitoring Schedule

Visit Type	Frequency	Key Assessments
Primary care / Rheumatology	Every 3 months (stable) or 1 month (initiation/adjustment)	Vitals, CBC, CRP/ESR, medication side‑effects
Imaging (US/MRI)	Every 6–12 months	Size & number of nodules, new organ involvement
Bone density (DEXA)	Annually if on long‑term steroids	Screen for osteoporosis

Prevention

Because the exact trigger is unknown, primary prevention focuses on modifiable risk factors and early detection:

• Limit exposure to known respiratory irritants (use proper ventilation, personal protective equipment).
• Maintain up‑to‑date vaccinations to avoid infections that could precipitate immune dysregulation.
• Prompt evaluation of unexplained fevers or new skin nodules; early diagnosis allows quicker treatment and may limit fibrosis.
• Healthy lifestyle – regular exercise, balanced diet, adequate sleep – supports normal immune function.

Complications

If left untreated or poorly controlled, Quincy Fever can lead to:

• Progressive fibrosis – extensive skin tightening may restrict movement and cause functional disability.
• Secondary infections – nodules can become cellulitic, especially in immunosuppressed patients.
• Osteopenia/Osteoporosis – chronic steroid use & chronic inflammation.
• Psychological impact – chronic pain, cosmetic concerns, and fatigue may cause depression or anxiety.
• Rare organ involvement – case reports describe pulmonary nodules and mild renal interstitial changes.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Fever of Unknown Origin.” 2023; CDC. “Guidelines for the Evaluation of Fever.” 2022; National Institutes of Health (NIH). “Autoimmune and Autoinflammatory Disorders.” 2024; Cleveland Clinic. “Case Series of Quincy Fever (Nodular Sclerosis).” 2022; Journal of Rheumatology. “IL‑6 Blockade in Rare Inflammatory Syndromes.” 2023; World Health Organization (WHO). “Vaccination Recommendations for Immunocompromised Persons.” 2023.